Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. May 7, 2012; 18(17): 2043-2052
Published online May 7, 2012. doi: 10.3748/wjg.v18.i17.2043
Published online May 7, 2012. doi: 10.3748/wjg.v18.i17.2043
Table 6 Survival analysis of patients with different methylation status
| Gene | M/U | n | Disease free survival | Overall survival | ||||||
| Estimate (mo) | Scope (mo) | Log-Rank | P value | Estimate (mo) | Scope (mo) | Log-Rank | P value | |||
| SPARC | M | 37 | 15.0 | 9.6-20.4 | 2.094 | 0.148 | 28.0 | 17.8-38.2 | 4.096 | 0.043 |
| U | 14 | 24.0 | 12.6-35.5 | 41.0 | 36.5-45.5 | |||||
-
Citation: Zhang Y, Yang B, Du Z, Bai T, Gao YT, Wang YJ, Lou C, Wang FM, Bai Y. Aberrant methylation of
SPARC in human hepatocellular carcinoma and its clinical implication. World J Gastroenterol 2012; 18(17): 2043-2052 - URL: https://www.wjgnet.com/1007-9327/full/v18/i17/2043.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i17.2043